Your browser doesn't support javascript.
loading
High-Throughput Microdissection for Next-Generation Sequencing.
Rosenberg, Avi Z; Armani, Michael D; Fetsch, Patricia A; Xi, Liqiang; Pham, Tina Thu; Raffeld, Mark; Chen, Yun; O'Flaherty, Neil; Stussman, Rebecca; Blackler, Adele R; Du, Qiang; Hanson, Jeffrey C; Roth, Mark J; Filie, Armando C; Roh, Michael H; Emmert-Buck, Michael R; Hipp, Jason D; Tangrea, Michael A.
Affiliation
  • Rosenberg AZ; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Armani MD; Pathogenetics Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Fetsch PA; Cytopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Xi L; Molecular Diagnostics Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Pham TT; Molecular Diagnostics Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Raffeld M; Molecular Diagnostics Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Chen Y; Pathogenetics Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
  • O'Flaherty N; Department of Mechanical Engineering, Johns Hopkins University, Baltimore, Maryland, United States of America.
  • Stussman R; Pathogenetics Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Blackler AR; Pathogenetics Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Du Q; Pathogenetics Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Hanson JC; Pathogenetics Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Roth MJ; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Filie AC; Cytopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Roh MH; Cytopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Emmert-Buck MR; Department of Pathology, University of Michigan, Ann Arbor, Michigan, United States of America.
  • Hipp JD; Pathogenetics Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Tangrea MA; Avoneaux Medical Institute, Oxford, Maryland, United States of America.
PLoS One ; 11(3): e0151775, 2016.
Article in En | MEDLINE | ID: mdl-26999048
ABSTRACT
Precision medicine promises to enhance patient treatment through the use of emerging molecular technologies, including genomics, transcriptomics, and proteomics. However, current tools in surgical pathology lack the capability to efficiently isolate specific cell populations in complex tissues/tumors, which can confound molecular results. Expression microdissection (xMD) is an immuno-based cell/subcellular isolation tool that procures targets of interest from a cytological or histological specimen. In this study, we demonstrate the accuracy and precision of xMD by rapidly isolating immunostained targets, including cytokeratin AE1/AE3, p53, and estrogen receptor (ER) positive cells and nuclei from tissue sections. Other targets procured included green fluorescent protein (GFP) expressing fibroblasts, in situ hybridization positive Epstein-Barr virus nuclei, and silver stained fungi. In order to assess the effect on molecular data, xMD was utilized to isolate specific targets from a mixed population of cells where the targets constituted only 5% of the sample. Target enrichment from this admixed cell population prior to next-generation sequencing (NGS) produced a minimum 13-fold increase in mutation allele frequency detection. These data suggest a role for xMD in a wide range of molecular pathology studies, as well as in the clinical workflow for samples where tumor cell enrichment is needed, or for those with a relative paucity of target cells.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Microdissection / High-Throughput Nucleotide Sequencing Limits: Animals / Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2016 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Microdissection / High-Throughput Nucleotide Sequencing Limits: Animals / Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2016 Document type: Article Affiliation country: